Archemix Names Page

Archemix Names Page
Bouchard Senior Vice President of Preclinical Drug Discovery and Development

 CAMBRIDGE, Mass., Nov. 4 /PRNewswire/ — Archemix Corp., the privately-held
biopharmaceutical company discovering and developing aptamer therapeutics,
announced today the appointment of Dr. Page Bouchard as Senior Vice President of
Preclinical Drug Discovery and Development. Dr. Bouchard will have
responsibility for directing the Company’s preclinical pharmacology, drug
metabolism and pharmacokinetics and drug safety efforts.

“Page has extensive experience in the area of preclinical drug discovery and
development and will lead this important multifunctional area at Archemix,” said
Dr. Errol De Souza, President and Chief Executive Officer of Archemix. “Page
possesses the unique combination of scientific experience and leadership skills
necessary to move our rapidly expanding pipeline of therapeutic aptamer leads
into clinical development. We are delighted to have Page as a part of our team
and look forward to his contributions to the development of aptamer therapeutic
products and the generation of shareholder value.”

“Archemix is at an exciting stage of its development,” commented Dr. Bouchard.
“The company’s aptamer technology has the potential to bring forth an entirely
new class of therapeutics for the treatment of acute and chronic diseases. I
look forward to leveraging my experience with both biotherapeutics and small
molecule drug candidates to this new class of therapeutics. The efficient
integration of preclinical and clinical development activities with novel
technology, rigorous science and focused strategic planning will lead to
significant product opportunities.”

Prior to joining Archemix, Dr. Bouchard was Vice President, Drug Safety
Evaluation at Millennium Pharmaceuticals. In this position, Dr. Bouchard led the
preclinical Drug Safety and Pathology organization, leading development projects
to critical clinical and regulatory milestones. Prior to joining Millennium, Dr.
Bouchard was Assistant Vice President of Pathology at Wyeth-Ayerst, heading the
discovery support pathology, toxicologic pathology, clinical pathology and
toxicogenomics efforts.

Dr. Bouchard received a bachelor’s degree from Wesleyan University and a D.V.M.
from Tufts University Veterinary School. He trained in veterinary pathology at
Cornell Veterinary School and is board certified in veterinary pathology by the
American College of Veterinary Pathologists.

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined
three-dimensional shapes, allowing them to bind to target molecules in a manner
that is conceptually similar to antibodies. Aptamers combine the optimal
characteristics of small molecules and antibodies, including high specificity
and affinity, chemical and biological stability, low toxicity and immunogenicity
and the ability to target protein-protein interactions. In contrast to
monoclonal antibodies, aptamers are chemically synthesized rather than
biologically expressed, offering a significant cost advantage. As therapeutic
agents, aptamers have demonstrated clinical biological efficacy and have
excellent, tunable pharmacokinetic properties.

About Archemix Corp.

Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge,
Massachusetts. The company’s mission is to develop aptamers as a class of
directed therapeutics for the treatment of human disease. Because of their
unique properties and proven efficacy, aptamers are a superior alternative to
biologics and small molecules and will be a major class of drugs for the
treatment of unmet medical needs.

Archemix’s aptamer expertise is complemented by a dominant patent estate
comprised of over 180 issued and 220 pending patents covering the
identification, composition and use of therapeutic aptamers. In addition to the
company’s core aptamer generation technology, Archemix possesses strong
expertise in both preclinical and clinical drug development. Further information
about Archemix can be found at

For further information or to speak with Dr. Errol De Souza or Dr. Page
Bouchard, please contact Davia Temin of Temin and Company at (212) 588-8788 or